Document:

<PAGE>

                              SETTLEMENT AGREEMENT

         This Settlement Agreement and Mutual General Release is entered into,
effective as of February 28, 2002 (the "Effective Date"), by and between W.
BRIAN FUERY ("FUERY"), STUNNER CORPORATION, a California corporation
("STUNNER"), U.S. CANCER MANAGEMENT CORPORATION, a Delaware corporation
("USCMC"), (all hereinafter sometimes referred to as "Defendants"), and the
USCMC-USCC Partnership, on the one hand, and U.S. CANCER CARE, INC., a Delaware
corporation ("USCC") and ONCURE TECHNOLOGIES CORP., a Florida corporation
("ONCURE"), (hereinafter sometimes jointly referred to as "Cross-Defendants"),
on the other hand.

         WHEREAS, USCC has filed a Complaint in Alameda County Superior Court,
entitled U.S. Cancer Care, Inc. vs. John J. Fuery, et al., action number
2001-028350 and,

         WHEREAS, Defendants have filed a Cross-Complaint in that same action,
entitled Brian Fuery, et al. vs. U.S. Cancer Care, Inc., et al.,

         WHEREAS, the parties now desire to settle and resolve all disputes that
exist between and among them that are connected to, arise out of or are related
to any of the claims referenced in the said litigation,

         NOW THEREFORE, the parties hereby agree as follows: Contemporaneously
with the execution of this Settlement Agreement and Mutual General Release by
all parties:

1.       A.       FUERY shall deliver to ONCURE 642,833 shares of ONCURE stock
                  that he currently owns in his name, free and clear from any
                  liens, claims, or encumbrances of any nature whatsoever,
                  together with a duly executed Stock Power transferring said
                  shares to ONCURE.

         B.       ONCURE shall pay to FUERY in cash the sum of Thirty-One
                  Thousand One-Hundred Twenty Dollars ($31,120.00).

         C.       There is currently an outstanding invoice from Randall Holt,
                  PhD Physicist, to ONCURE for $32,780.00 (the "Holt Invoice").
                  A copy of the Holt Invoice is attached hereto as Exhibit A.
                  Contemporaneously with the execution of this Settlement
                  Agreement and Mutual General Release by all parties, ONCURE
                  shall pay one-half of the Holt Invoice (Sixteen Thousand Three
                  Hundred Ninety Dollars $16,390.00) directly to Randall Holt,
                  PhD by having a check in that amount delivered to USCMC for
                  delivery to Randall Holt, PhD. USCMC shall pay the remaining
                  half of the Holt Invoice (Sixteen Thousand Three Hundred

                                                                     Page 1 of 9

<PAGE>
                  Ninety Dollars $16,390.00) to Randall Holt PhD, within thirty
                  (30) days of the Effective Date of this Settlement Agreement
                  and Mutual General Release.

         D.       USCC shall quitclaim, contribute and deliver to USCMC all the
                  furniture and equipment currently used by and in the
                  possession of USCMC at the offices leased by ONCURE at 700
                  Ygnacio Valley Road, Suite 300, Walnut Creek, California
                  ("ONCURE's Walnut Creek Office"), and any furniture and
                  equipment currently in the Ceres Warehouse, including any and
                  all equipment in the office previously occupied by Doug
                  McBride while he was an ONCURE employee (collectively, the
                  "Walnut Creek Furniture and Equipment") by means of a Bill of
                  Sale in the form attached hereto as Exhibit B.

         E.       Subject to the full performance of the obligations set forth
                  in the succeeding sentence, USCMC may occupy ONCURE's Walnut
                  Creek Office for as long as it, in its sole discretion,
                  determines, but in no event longer than twelve months
                  following the Effective Date of this Settlement Agreement and
                  Mutual General Release. In consideration for the right to
                  occupy ONCURE's Walnut Creek Office, beginning March 1, 2002,
                  USCMC shall pay ONCURE Two Thousand Five Hundred Dollars
                  ($2,500.00) per month in rent within five (5) business days of
                  receiving adequate evidence that ONCURE has paid the rent to
                  the Landlord. ONCURE, in turn, covenants and agrees to pay the
                  full monthly rent owed to the landlord of ONCURE's Walnut
                  Creek Office in a timely manner so as to insure that USCMC may
                  remain in the premises pursuant to the terms of this paragraph
                  1E. In addition, USCMC and ONCURE will use their best efforts
                  to (i) find suitable alternative office space for USCMC in the
                  same building as ONCURE's Walnut Creek Office and (ii) secure
                  from the landlord a termination of ONCURE's lease for ONCURE's
                  Walnut Creek Office.

         F.       Within 15 days of the Effective Date of this Settlement
                  Agreement and Mutual General Release, ONCURE shall deliver to
                  USCMC a Letter of Credit issued from a federally chartered
                  bank in the amount of twenty seven thousand, one hundred
                  dollars ($27,100.00) to be held by USCMC as security for the
                  faithful performance by ONCURE of its rent payment obligations
                  to the landlord of the Walnut Creek Office. Provided ONCURE is
                  not in default of its rent payment obligations to the landlord
                  of the Walnut Creek Office, at the earlier of the first
                  anniversary of the Effective Date of this Settlement Agreement
                  and Mutual General Release or the termination of the lease for
                  ONCURE's Walnut Creek Office as contemplated in the last
                  sentence of the preceeding paragraph 1E, USCMC shall return
                  the Letter of Credit to ONCURE. If at any time during the
                  twelve month period following the Effective Date of this
                  Settlement Agreement and Mutual General Release that USCMC
                  occupies ONCURE's Walnut Creek Office ONCURE fails to pay its
                  rent obligations to the landlord where such failure to pay
                  continues for a period of ten (10) days after written notice
                  thereof

                                                                     Page 2 of 9

<PAGE>

                  from USCMC to ONCURE, USCMC may, provided it is not in default
                  of its rent obligations to ONCURE as provided in paragraph 1E
                  above, appropriate and apply any portion of the Letter of
                  Credit provided pursuant to this paragraph 1F to payment of
                  overdue rent to the landlord of the Walnut Creek Office.
                  Should ONCURE not deliver the Letter of Credit as required
                  herein, then this entire Agreement shall be null and void.

         G.       USCMC shall assume and agree to pay when due all obligations
                  of ONCURE arising under or in connection with that certain
                  Promissory Note dated August 9, 2001 issued by ONCURE to the
                  order of Jeff Summers in the original principal amount of One
                  Hundred Sixty Thousand Dollars ($160,000.00)(the "Summers
                  Note") and provide ONCURE with a release of any liability
                  under the Summers Note. A copy of the Summers Note is attached
                  hereto as Exhibit C. USCMC hereby further agrees to defend and
                  indemnify ONCURE, and hold ONCURE harmless, from and against
                  any and all claims, demands, causes of action, expenses
                  (including, without limitation, reasonable attorneys' fees),
                  judgments and the like arising out of, or in connection with,
                  the Summers Note.

         H.       Cross-Defendants shall quitclaim, transfer and deliver to
                  FUERY any ownership rights they may have in the USCMC-USCC
                  Partnership, a California General Partnership, and execute any
                  and all documents requested of them to accomplish this result.

         I.       ONCURE shall, contemporaneously with the execution of this
                  Settlement Agreement and Mutual General Release, execute and
                  consent to an assignment agreement, in any form required by
                  The Permanente Medical Group, whereby The Permanente Medical
                  Group agrees to assign The Professional Services Agreement for
                  Radiology Services to USCMC.

         J.       The parties hereto further agree to the following release
                  terms:

2.                             MUTUAL RELEASE AGREEMENT
                               ------------------------

         For the consideration above referenced, and with the exception of the
         representations, understandings, promises and obligations arising under
         this Settlement Agreement and Mutual General Release, each party, being
         of lawful age, on behalf of himself or itself and each party's heirs,
         successors, administrators, personal representatives, executors,
         assigns, agents, insurers, officers, directors, shareholders,
         employees, principals, partners, servants and employees, hereby:

                                                                     Page 3 of 9

<PAGE>

         A.       Fully releases, acquits and forever discharges each of the
                  other parties to this Settlement Agreement and Mutual General
                  Release, including their representatives, agents, servants,
                  employees, heirs, successors, administrators, executors,
                  attorneys, co-partners, co-venturers, insurers, stockholders,
                  predecessors, officers, directors, shareholders, parent and
                  subsidiary organizations, affiliates and assigns (hereinafter
                  referred to as "Releasees") of and from any and all actions,
                  causes of action, rights, claims, demands, damages, costs,
                  loss of service, expenses, liabilities, attorneys' fees, and
                  debts whatsoever, in law or in equity, whether known or
                  unknown, suspected or unsuspected which each party may now
                  have against the Releasees based upon, related to, arising out
                  of, or in anyway connected with the matters alleged in, or
                  that could have been alleged in, that certain Complaint filed
                  October 23, 2001, in the Superior Court of the State of
                  California, County of Alameda, entitled U.S. CANCER CARE, INC.
                  vs. JOHN J. FUERY, et al., and that certain Cross-Complaint
                  filed in the same action entitled BRIAN FUERY et al. vs. U.S.
                  CANCER CARE, INC. et al., Action No. 2001-028350 (the
                  "Action"), including, without limitation, any facts, matters,
                  and circumstances alleged in those or any subsequent or prior
                  pleadings in the Action or any facts arising out of any
                  discovery in said Action and any obligations of the parties
                  identified in this Settlement Agreement and Mutual General
                  Release to refrain from competing with the other, pursuant to
                  any prior agreements between the parties to this Agreement.
                  The parties expressly understand and agree that nothing in
                  this Settlement Agreement and Mutual General Release,
                  including, but not limited to, this paragraph 2(A) is intended
                  to nor does it release any claims any parties hereto may have
                  against John J. Fuery, M.D. or the Oncology Corporation, a
                  California corporation.

                  As a material part of the consideration for this Mutual
                  General Release, each of the parties hereto, as necessary and
                  appropriate, shall forthwith upon this Settlement Agreement
                  and Mutual General Release becoming effective, as hereinafter
                  set forth, cause a Request for Dismissal with Prejudice, to be
                  filed in the Action so as to cause a dismissal with prejudice
                  of any and all claims or causes of action asserted against
                  U.S. CANCER CARE, INC., a Delaware corporation, ONCURE
                  TECHNOLOGIES CORP., a Florida corporation, BRIAN FUERY,
                  STUNNER CORPORATION, a California corporation and U.S. CANCER
                  MANAGEMENT CORPORATION, a Delaware corporation.

         B.       Agrees to refrain and forebear from commencing, instituting or
                  participating in, either as a named or unnamed party, any
                  lawsuit, action or other proceedings against Releasees,
                  whether brought by any party, or by others on each party's
                  behalf, based on or arising out of any of the facts or
                  circumstances described in Paragraph 2(A) above.

                                                                     Page 4 of 9

<PAGE>

         C.       Agrees that no representation or promise not expressly
                  contained in this Settlement Agreement and Mutual General
                  Release has been made and further acknowledges that each party
                  is not entering into this Settlement Agreement and Release on
                  the basis of any promise or representation, express or
                  implied, not otherwise contained herein. This Settlement
                  Agreement and Release contains the entire agreement between
                  the parties hereto and the terms hereof are contractual and
                  not a mere recital. This Settlement Agreement and Release
                  supersedes any prior agreement and contains the entire
                  agreement of the parties on the matters covered. Each party
                  hereto has fully and personally investigated the subject
                  matters of this Settlement Agreement Release Agreement,
                  consulted such independent counselors as required, and do not
                  rely on any statement of fact or opinion of any other party to
                  this Settlement Agreement and Release.

         D.       Acknowledges and agrees that this Mutual General Release is a
                  release of all claims for injuries and damages to person
                  and/or property, whether such injuries and damages be known or
                  unknown, foreseen or unforeseen, patent or latent that each
                  party may have against the Releasees.

         E.       Acknowledges and agrees that he or it has read and fully
                  understands the statutory language of Section 1542 of the
                  Civil Code of the State of California and on that basis
                  expressly and specifically waives application of California
                  Code of Civil Code Section 1542, which reads as follows:

                  "A general release does not extend to claims which the
                  creditor does not know or suspect to exist in his favor at the
                  time of executing the release, which if known by him must have
                  materially affected his settlement with the debtor."

         F.       Agrees that he or it has not, nor will in the future, assign,
                  hypothecate, transfer, pledge or purport to do so, in any
                  manner, to any entity, person, or corporation, any claim,
                  action, right, demand, or cause of action based on, or arising
                  out of or in connection with, any matter, fact or thing
                  described in Paragraph 1 above. The parties further agree
                  that, with the exception of the claims set forth in the
                  Complaint and Cross-Complaint in the Action, there is no
                  litigation pending with respect to the facts, circumstances,
                  matters or events, which are the subject matter hereof, and
                  that no party hereto has pledged said rights as security for
                  performance of any obligation or otherwise encumber said
                  rights.

3.       Each party hereto acknowledges and agrees that this Settlement
         Agreement and Mutual General Release is a compromise of disputed
         claims, and that the payments made hereunder are not to be construed as
         an admission of liability on the part of any party hereto, by whom such
         liability is expressly denied.

                                                                     Page 5 of 9

<PAGE>

4.       Each party hereto agrees that in the event any party hereto engages the
         services of an attorney to bring suit to enforce, interpret, or
         otherwise construe the whole or any part of this Settlement Agreement
         and Mutual General Release, or for damages on account of any breach of
         covenant contained herein, or to quiet title, or to enforce any other
         claim or cause of action arising out of the circumstances surrounding
         the execution of this Settlement Agreement and Mutual General Release,
         the prevailing party in any such litigation shall be entitled to
         recover from the other reasonable attorneys' fees and costs incurred
         therein as part of any judgment awarded by the court or settlement in
         which such litigation is sought to be determined.

5.       Each party hereto acknowledges that the parties to this Settlement
         Agreement and Mutual General Release have been represented by
         independent counsel of their own choosing, or have been afforded
         sufficient opportunity so to do, with respect to this transaction, and
         the preparation and execution of this Settlement Agreement and Mutual
         General Release. Each party hereto hereby acknowledges, understands and
         agrees that this Agreement and Release has been executed voluntarily
         and of each party's own free will, that each party has been represented
         by, or has been afforded sufficient opportunity to consult independent
         income tax, legal, real estate and other such advisors of their own
         choice and that each party's decision to execute this Agreement is
         based upon his own independent consultations with such independent
         advisers and not upon any advice, inducements or representations by any
         other party hereto, or by any person, firm or entity on their behalf,
         except as specifically set forth herein. Each party and/or his or its
         counsel have reviewed this Settlement Agreement and Mutual General
         Release and specifically agree that any rule of construction, to the
         effect that ambiguities are to be resolved against the drafting party,
         shall not apply to the interpretation of this Agreement and Release.

6.       The parties hereto agree that time is of the essence with respect to
         all aspects of this Settlement Agreement and Mutual General Release.

7.       Other than as set forth in paragraph 4, hereinabove, the parties hereto
         shall bear their own expenses, including all attorneys' fees and costs,
         incurred in connection with the Action.

8.       The parties hereto agree that this Settlement Agreement and Mutual
         General Release contains the entire agreement of the parties hereto and
         supersedes any prior written or oral agreements between them concerning
         the subject matter contained herein. There are no representations,
         agreements, arrangements or understandings, oral or written, between or
         among the parties hereto, relating to the subject matter contained in
         this Settlement Agreement and Mutual General Release which are not
         fully expressed herein.

9.       The parties hereto agree that all words used in this Settlement
         Agreement and Mutual General Release shall be construed to include the
         plural as well as the singular number, and words used herein in the
         present tense shall include the future as well as the past, and words
         used in the masculine gender shall include the feminine and neuter
         gender. Should

                                                                     Page 6 of 9

<PAGE>

         any provision of this Settlement Agreement and Mutual General Release
         require judicial interpretation, it is agreed that the court
         interpreting or construing the same shall not apply a presumption that
         the terms hereof shall be more strictly construed against one (1) party
         by reason of the rule of construction that a document is to be
         construed more strictly against the person who himself or through his
         agent prepared the same, it being agreed that both parties have
         participated in the preparation hereof. The provisions of this
         Settlement Agreement and Mutual General Release are severable and the
         invalidity of any portion shall not invalidate the remainder.

10.      No amendment, modification, change or alteration of the terms and
         conditions of this Settlement Agreement and Mutual General Release
         shall be effective for any purpose whatever unless reduced to writing
         and signed by all of the parties hereto.

11.      This Settlement Agreement and Mutual General Release shall become
         effective upon execution of the Settlement Agreement and Mutual General
         Release by all parties hereto, which may be accomplished by way of
         counterparts. Upon full execution, the effective date of this
         Settlement Agreement and Mutual General Release shall be deemed the
         date first shown above.

12.      The parties hereto agree that the terms of this Settlement Agreement
         and Mutual General Release shall bind and inure to the benefit of the
         respective heirs, personal representatives, successors in interest and
         assigns of each of the parties hereto; and the terms of this Agreement
         and Release, when applicable, shall survive the execution of any deed,
         promissory note, deed of trust or close of escrow for the consummation
         of this transaction.

13.      Any Notice(s) required under this Settlement Agreement and Mutual
         General Release shall be sent to as follows:
         To Cross-Defendants: Rick Baker, OnCure Technologies Corp., 7450 East
         River Road, Suite 3, Oakdale California 95361
         To Defendants: W. Brian Fuery, 700 Ygnacio Valley Road, Suite 300,
         Walnut Creek, California 94596.

14.      This Settlement Agreement and Mutual General Release shall be construed
         and interpreted in accordance with the laws of the State of California
         and venue for any disputes shall be in Contra Costa, California.

THE PARTIES ACKNOWLEDGE THAT EACH PARTY HERETO HAS CAREFULLY READ THE FOREGOING,
INCLUDING, BUT NOT LIMITED TO, THE RELEASE AGREEMENT AND KNOWS THE CONTENTS
THEREOF, AND THAT EACH PARTY SIGNS THE SAME AS HIS OR ITS OWN FREE ACT.

                                                                     Page 7 of 9

<PAGE>

             CAUTION - THIS CONTAINS A RELEASE - READ BEFORE SIGNING

Dated: February 28, 2002                             /s/ W. Brian Fuery
                                                     --------------------------
                                                     W. BRIAN FUERY

Dated: February 28, 2002                             STUNNER CORPORATION

                                                     /s/ W. Brian Fuery
                                                     --------------------------
                                                     By: President

Dated: February 28, 2002                             U.S. CANCER MANAGEMENT
                                                     CORPORATION

                                                     /s/ W. Brian Fuery
                                                     --------------------------
                                                     By:  General Partner

Dated: February 28, 2002                             USCMC-USCC PARTNERSHIP

                                                     /s/ W. Brian Fuery
                                                     --------------------------
                                                     By:  General Partner

Dated: February 28, 2002                             U.S. CANCER CARE, INC.

                                                     /s/ Jeffrey A. Goffman
                                                     --------------------------
                                                     By:  President

Dated: February 28, 2002                             ONCURE TECHNOLOGIES, CORP.

                                                      /s/ Jeffrey A. Goffman
                                                      --------------------------
                                                      By: President

                                                                     Page 8 of 9

<PAGE>

APPROVED AS TO FORM:

Dated: February 28, 2002                          LAW OFFICES OF STEPHEN M. KASS
                                                  Professional Corporation

                                                  /s/ Stephen M. Kass
                                                  --------------------------
                                                  By:  Stephen M. Kass

Dated: February 28, 2002                          JONES, BOTHWELL & DION, LLP

                                                  /s/ Paul J. Dion
                                                  --------------------------
                                                  By:  Paul J. Dion

                                                                     Page 9 of 9<PAGE>

                               PURCHASE AGREEMENT
                               ------------------

         THIS PURCHASE AGREEMENT dated as of December 23, 2003 (this
"Agreement"), is by and between ONCURE TECHNOLOGIES CORP., a Florida corporation
(the "Company"), and ALPINE VENTURE CAPITAL PARTNERS LP, a Delaware limited
partnership (the "Investor").

                                    RECITALS:
                                    ---------

         A. The Investor desires to purchase from the Company, and the Company
desires to issue and sell to the Investor, a convertible promissory note of the
Company in the aggregate principal amount of $500,000 upon the terms and subject
to the conditions contained herein.

         B. The Company and the Investor entered into that certain Purchase
Agreement, dated May 15, 2002 (the "Prior Agreement"), pursuant to which the
Investor purchased from the Company a convertible promissory note in the
aggregate principal amount of $1,000,000 (the "May Note").

                                    AGREEMENT
                                    ---------
         NOW, THEREFORE, for good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound, agree as follows:

                                   ARTICLE I
                          ISSUANCE AND SALE OF THE NOTE
                          -----------------------------

         SECTION 1.1 Purchase and Sale of the Note. Subject to all of the terms
and conditions hereof and in reliance on the representations and warranties set
forth herein, at the Closing (as defined below) the Company shall issue and sell
to the Investor, and the Investor shall purchase from the Company, the Company's
Convertible Promissory Note in the form attached hereto as Exhibit A (the
"Note") in the aggregate principal amount of $500,000 for an aggregate purchase
price of $500,000 (the "Purchase Price").

         SECTION 1.2 Closing; Conditions to Closing.

            (a) The closing (the "Closing") of the sale of the Note shall occur
on the date hereof (the "Closing Date") upon the execution and delivery of this
Agreement.

            (b) At the Closing:

                (i) the Company will deliver to the Investor (A) the Note and
                (B) the SBIC investment letter, in substantially the form
                attached hereto as Exhibit B;

<PAGE>

                (ii) the Company will pay all reasonable legal fees and expenses
                owed by the Investor to its counsel, incurred in connection with
                this Agreement; provided, that the Investor delivers invoices
                and other evidences of such expenses and the amount of all such
                fees, costs and expenses does not exceed $25,000 in the
                aggregate; and

                (iii) the Investor, in full payment for the Note, will deliver
                to the Company in immediately available funds, by wire transfer
                to such account as the Company shall specify, the Purchase
                Price.

         SECTION 1.3 Post-Closing Deliveries. On or prior to the tenth day
following the Closing, the Company will deliver the Investor:

            (a) a copy: (i) of the Company's Charter, certified by the Florida
Secretary of State to be true and complete as of a date no more than ten (10)
days after the Closing Date, and (ii) (A) the Company's Charter and (B) the
Company's by-laws, each certified by the Secretary of the Company to be true and
complete as of the Closing Date.

                                   ARTICLE II
            REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF THE COMPANY
            ---------------------------------------------------------

         The Company represents and warrants to, and agrees with, the Investor
as follows:

            SECTION 2.1 Organization, etc. The Company has been duly formed and
is validly existing as a corporation in good standing under the laws of the
State of Florida and is qualified to do business as a foreign corporation in
each jurisdiction in which the failure to be so qualified would have a material
adverse effect on the assets, liabilities, condition (financial or other),
business, results of operations or prospects (excluding, with respect to
prospects, general economic conditions and matters affecting the industry in
which the Company operates that are not specific to the Company) of the Company
(a "Material Adverse Effect"). The Company has all requisite corporate power and
authority, and all necessary authorizations, approvals, oreders, licenses,
certificates and permits, to own, lease and operate its properties and to
conduct its business as presently conducted and to enter into, execute, deliver
and perform all of its duties and obligations under this Agreement and all
related instruments and agreements executed in connection herewith. The Company
is not in violation of any term of any agreement, instrument, judgment, decree,
order, statute, rule or government regulation applicable to the Company or to
which the Company is a party or to which its assets are subject which would, in
any individual instance, or in any series of related instances, have a Material
Adverse Effect.

            SECTION 2.2 Corporate Power. The Company has all requisite legal and
corporate power to enter into, execute and deliver this Agreement, to issue and
sell the Note, the Underlying Shares issuable upon conversion of the Note, and
the shares of Common Stock issuable upon conversion

<PAGE>

of the Underlying Shares and to carry out and perform its obligations under the
terms of this Agreement.

         SECTION 2.3 Authorization. This Agreement is the valid and binding
obligation of the Company enforceable against the Company in accordance with its
terms. The execution, delivery and performance of this Agreement and the
consummation of the transaction contemplated hereby have been duly authorized by
all necessary corporation action of the Company.

         SECTION 2.4 Subsidiaries.

            (a) Except as set forth on Schedule 2.4(a) hereto, the Company does
not have any Subsidiaries and does not own or hold of record and/or beneficially
own or hold, directly or through a Subsidiary, any shares of any class of the
capital of any corporation or any legal or beneficial ownership interest in any
general or limited partnership, limited liability company, business trust or
joint venture or in any other unincorporated trade or business enterprise.

            (b) Each of the Company's Subsidiaries is duly organized, validly
existing and in good standing in its jurisdiction of incorporation and is duly
qualified as a foreign corporation and authorized to do business in all other
jurisdictions in which the nature of its business or property makes such
qualification necessary, except where the failure to so qualify would not have a
Material Adverse Effect. Each of the Company's Subsidiaries has all requisite
corporate power and authority, and all necessary authorizations, approvals,
orders, licenses, certificates and permits, to own, lease and operate its
properties and to conduct its business as presently conducted, as proposed to be
conducted, except where the failure to obtain such authorization, approval,
order, license, certificate or permit would not have a Material Adverse Effect.

         SECTION 2.5 Validity of Shares. The shares of Series H Stock issuable
upon conversion of the Note and the shares of Common Stock issuable upon
conversion of the Series H Stock have been duly and validly reserved. Upon
issuance in accordance with the provisions of the Note, the Series H Stock will
be duly and validly issued, fully paid, non-assessable and free and clear of all
liens, charges, claims and encumbrances (other than any created by the
Investor).

         SECTION 2.6 Capitalization. As of the date hereof, the authorized
Capital Stock of the Company consists of 100,000,000 shares of Common Stock and
1,000,000 shares of Preferred Stock (of which 1,000 shares have been designated
as Series H Stock). Without giving effect to the transactions contemplated by
this Agreement, the issued and outstanding Capital Stock of the Company consists
solely of (i) 8,759,879 shares of Common Stock, (ii) 1,000 shares of Series C
Cumulative Accelerating Redeemable Preferred Stock, (iii) 1,000 shares of Series
D Cumulative Accelerating Redeemable Preferred Stock, and (iv) 1,000 shares of
Series E Cumulative Accelerating Redeemable Preferred Stock. Except as set forth
on Schedule 2.6, there are no outstanding rights (either pre-emptive or other)
or options to subscribe for or purchase from the Company, or any warrants or
other agreements providing for or requiring the issuance or purchase

<PAGE>

by the Company of, any Capital Stock or any securities convertible into or
exchangeable, for, or exercisable into, its Capital Stock (other than the shares
of Preferred Stock described in clauses (ii), (iii) and (iv) above) or any
voting trusts, proxies or agreements relating to the voting of the Company's
Capital Stock.

         SECTION 2.7 Governmental Consents. The execution and delivery by the
Company of this Agreement and the performance by the Company of this Agreement
and the transactions contemplated hereby, do not and will not require any
registration with, consent or approval of, or notice to, with or by, any
federal, state or other governmental authority or regulatory body, other than
the periodic and other filings under the Exchange Act or as required to comply
with the obligations of the Company under the Registration Rights Agreement.

         SECTION 2.8 No Violation. The execution and delivery of this Agreement
will not (i) except as set forth in Schedule 2.8, conflict with or result in a
breach of any provision of the articles of incorporation or by-laws of the
Company, (ii) to the Company's knowledge, except as set forth in Schedule 2.8,
result in a material default or breach of, or require any consent, approval,
authorization or permit of, or filing or notification to, any Person, company or
entity under any of the terms, conditions or provisions of any note, bond,
mortgage, indenture, loan, factoring arrangement, license, agreement, lease or
other instrument or obligation to which the Company or any of its Subsidiaries
is a party, or by which the Company or any Subsidiary or any of their assets may
be bound, or (iii) violate any law, judgment, order, writ, injunction, decree,
statute, rule or regulation of any court, administrative agency, bureau, board,
commission, office, authority, department or other governmental entity
applicable to the Company or any Subsidiary thereof which violation would have a
Material Adverse Effect on the Company and its Subsidiaries, taken as a whole.

         SECTION 2.9 Issuances of Securities. The offering, issuance, sale and
delivery of the Note (and the issuance of the Underlying Shares issuable upon
conversion of the Note and the shares of Common Stock, if any, issuable upon
conversion of the Underlying Shares) as contemplated by this Agreement are
exempt from the registration and prospectus delivery requirements of the
Securities Act, are being made in compliance with all applicable state and
federal laws and regulations concerning the offer, issuance and sale of
securities, and are not being issued in violation of any preemptive or other
rights of any stockholder of the Company. The parties hereto agree and
acknowledge that in making the representations and warranties in the foregoing
sentence of this Section 2.9, the Company is relying on the representations and
warranties made by the Investor in Section 3.4.

         SECTION 2.10 Absence of Certain Developments. Except as disclosed in
the Company's reports filed with the Securities and Exchange Commission pursuant
to the Exchange Act or as otherwise disclosed herein (including the schedules
hereto), since September 30, 2002 there has been: (i) no material adverse change
in the condition, financial or otherwise, of the Company or its Subsidiaries,
taken as a whole, or in the assets, liabilities, properties or business of the
Company or

<PAGE>

its Subsidiaries, taken as a whole; (ii) no declaration, setting aside or
payment of any dividend or other distribution with respect to, or any direct or
indirect redemption or acquisition of, any Capital Stock of the Company or its
Subsidiaries; (iii) no waiver of any valuable right of the Company or its
Subsidiaries or cancellation of any material debt or claim held by the Company
or its Subsidiaries; (iv) no increase, direct or indirect, in the compensation
paid or payable to any officer, director, employee, agent or shareholder of the
Company or any Subsidiary (other than salary increases in the ordinary course of
business consistent with past practice which, individually or in the aggregate,
are not material); (v) no material loss, destruction or damage to any property
of the Company or any Subsidiary whether or not insured; (vi) no change in the
senior management or other key personnel of the Company or any Subsidiary with
whom the Company or any Subsidiary has a written employment agreement, or the
terms and conditions of their employment; (vii) no acquisition or disposition of
any assets (or any contract or arrangement therefor) nor any other material
transaction by the Company or any Subsidiary otherwise than for fair value in
the ordinary course of business consistent with past practice; or (viii) no
agreement or understanding, whether in writing or otherwise, for the Company or
any Subsidiary to take any actions specified in clauses (i) through (vii).

         SECTION 2.11 Commission Filings. The Company has filed all required
forms, reports and other documents with the Commission for periods from and
after December 31, 2001 (collectively, the "Commission Filings"), each of which
has complied in all material respects with all applicable requirements of the
Securities Act and the Exchange Act. The Company has heretofore made available
to the Investor all of the Commission Filings, including the Company's Annual
Report on Form 10-KSB for the year ended December 31, 2001. As of their
respective dates, the Commission Filings (including all exhibits and schedules
thereto and documents incorporated by reference therein) did not contain any
untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements made, in light of the circumstances under which
they were made, not misleading. The audited financial statements and unaudited
interim financial statements of the Company included or incorporated by
reference in such Commission Filings have been prepared in accordance with GAAP
(except as may be indicated in the notes thereto or, in the case of the
unaudited statements, as permitted by Form 10-QSB), complied as of their
respective dates in all material respects with applicable accounting
requirements and the published rules and regulations of the Commission with
respect thereto, and fairly present the financial position of the Company as of
the dates thereof and the results of operations for the periods then ended
(subject, in the case of any unaudited interim financial statements, to the
absence of footnotes required by GAAP and normal year-end adjustments).

         SECTION 2.12 Taxes. The Company and its Subsidiaries have filed all Tax
returns that are required to have been filed by it under applicable federal,
state or local law, and have paid all Taxes shown to be due and payable on such
returns and all other Taxes and assessments levied upon them or their
properties, assets, income or franchises, to the extent such Taxes and
assessments have become due and payable and before they have become delinquent,
except for any Taxes and assessments (i) the amount of which is not individually
or in the aggregate material or

<PAGE>

(ii) the amount, applicability or validity of which is currently being contested
in good faith by appropriate proceedings and with respect to which the Company
or its Subsidiary, taken as a whole, has established adequate reserves in
accordance with GAAP. The Company knows of no basis for any other Tax or
assessment that could reasonably be expected to have a Material Adverse Effect.
The charges, accruals and reserves on the books of the Company and its
Subsidiaries, taken as a whole, in respect of federal, state or other Taxes for
all fiscal periods are adequate.

         SECTION 2.13 Litigation. Except as set forth on Schedule 2.13 or as
disclosed in the Company's reports filed with the Securities and Exchange
Commission pursuant to the Exchange Act, there are no actions, suits or
proceedings pending or, to the knowledge of the Company, threatened against or
affecting the Company or any Subsidiary or any property of the Company or any
Subsidiary in any court or before any arbitrator of any kind that, individually
or in the aggregate, could reasonably be expected to have a Material Adverse
Effect.

         SECTION 2.14 Compliance with Law. The Company and each Subsidiary is in
compliance with all applicable laws, regulations, orders, judgments, decrees,
permits, licenses, franchises and authorizations, except where the failure to so
comply would not have a Material Adverse Effect. Neither the Company nor any
Subsidiary is in default under, or in violation of, or has violated (and not
cured such violation) any law (including, without limitation, laws relating to
the provision of healthcare services, issuance or sale of securities, antitrust,
zoning and building codes and ordinances, occupational safety, the protection of
the environment, transportation, storage or disposal of hazardous waste,
anti-pollution and air and water quality laws), or any licenses, franchises,
permits, authorizations or concessions granted by, or any judgment, decree,
writ, injunction or order of, any governmental or regulatory authority,
applicable to its business or any of its properties or assets, except where such
defaults and violations would not, in the aggregate, have a Material Adverse
Effect.

         SECTION 2.15 Registration Rights. Except as set forth in Schedule 2.15
hereto, and except for the rights granted to the Investor pursuant to the
Registration Rights Agreement, no Person has demand or other registration rights
to cause the Company to file any registration statement under the Securities Act
relating to the securities of the Company or any right to participate in any
such registration statement.

         SECTION 2.16 Insurance. There is in full force and effect certain
policies of insurance issued by insurers of recognized responsibility,
including, without limitation, fire and casualty insurance, insuring the Company
and its Subsidiaries and their properties against such losses and risks, and in
such amounts, as are usual and customary in the case of Companies engaged in the
same or similar business and similarly situated.

         SECTION 2.17 Transaction Costs. The Company is not obligated for any
Transaction Costs relating to the transactions contemplated by this Agreement.

<PAGE>

                                  ARTICLE III
           REPRESENTATIONS, WARRANTIES AND AGREEMENTS OF THE INVESTOR
           ----------------------------------------------------------

         The Investor represents and warrants to, and agrees with, the Company
as follows:

         SECTION 3.1 Organization, Good Standing And Qualification. The Investor
has been duly formed and is validly existing as a limited partnership in good
standing under the laws of the State of Delaware. The Investor has all requisite
power and authority, and all necessary authorizations, approvals, orders,
licenses, certificates and permits, to own, lease and operate its properties and
to conduct its business as presently conducted and to enter into, execute,
deliver and perform all of its duties and obligations under this Agreement and
all related instruments and agreements executed in connection herewith. The
Investor is not in violation of any term of any agreement, instrument, judgment,
decree, order, statute, rule or government regulation applicable to the Investor
or to which the Investor is a party or to which its assets are subject which
would, in any individual instance, or in any series of related instances, have a
material adverse effect on the Investor.

         SECTION 3.2 Authority. This Agreement is the valid and binding
obligation of the Investor enforceable against the Investor in accordance with
its terms. The execution, delivery and performance of this Agreement and the
consummation of the transaction contemplated hereby have been duly authorized by
all necessary action of the Investor.

         SECTION 3.3 Validity. This Agreement has been duly executed and
delivered by the Investor and is the lawful, valid and legally binding
obligation of the Investor, enforceable in accordance with its terms.

         SECTION 3.4 Investment Representations.

            (a) The Investor acknowledges that the offer and sale of the Note
has not been, nor will the Underlying Shares issuable upon conversion of the
Note be, registered under the Securities Act, or the securities laws of any
state or regulatory body and are being offered and sold in reliance upon
exemptions from the registration requirements of the Securities Act and such
laws and may not be transferred or resold without registration under such laws
unless an exemption is available. The Note and any certificate for any of the
Underlying Shares will be imprinted with a legend in substantially the following
form:

            "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
            REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE
            SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED,
            ASSIGNED, PLEDGED, HYPOTHECATED, OR OTHERWISE DISPOSED OF EXCEPT
            PURSUANT TO A REGISTRATION STATEMENT WITH RESPECT TO SUCH SECURITIES
            WHICH IS EFFECTIVE UNDER SUCH ACT AND UNDER ANY APPLICABLE STATE
            SECURITIES LAWS

<PAGE>

            UNLESS, IN THE OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
            COMPANY, AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT
            AND STATE SECURITIES LAWS IS AVAILABLE."

            (b) The Investor is acquiring the Note and the Underlying Shares
issuable upon conversion thereof, for investment and not with a view to the
resale or distribution thereof and is acquiring such securities for its own
account.

            (c) The Investor is an "accredited investor" (as that term is
defined in Rule 501 of Regulation D promulgated under the Securities Act), is
sophisticated in financial matters and is familiar with the business of the
Company so that it is capable of evaluating the merits and risks of its
investment in the Company and has the capacity to protect its own interests. The
Investor has had the opportunity to investigate on its own the Company's
business, management and financial affairs and has had the opportunity to review
the Company's operations and facilities and to ask questions and obtain whatever
other information concerning the Company as the Investor has deemed relevant in
making its investment decision.

            (d) The Investor owns 500 shares of the Series E Cumulative
Accelerating Redeemable Preferred Stock of the Company, and, in accordance with
its rights pertaining thereto, has designated a member of the Board of Directors
of the Company, John H. Zeeman.

                                   ARTICLE IV
          AMENDMENTS TO THE NOTE AND THE REGISTRATION RIGHTS AGREEMENT
          ------------------------------------------------------------

         SECTION 4.1 Amendment to the Registration Rights Agreement. Each of the
Company and the Investor hereby agrees to amend and restate the definition of
the term "Registrable Securities" in its entirety as follows:

            " 'Registrable Securities' means (i) the shares of Common Stock into
which the Investor's shares of (A) Series H Stock (now owned or hereafter
acquired) are convertible, (B) preferred stock acquired upon conversion of that
certain convertible promissory note issued by the Company on December 23, 2002
(the "Note Shares") are convertible and (ii) any additional shares of Common
Stock acquired by the Investor by way of a dividend, stock split or other
distribution in respect of the Series H Stock, the Note Shares and any other
shares of Common Stock. As to any particular Registrable Securities, once issued
such securities shall cease to be Registrable Securities when (i) a Registration
Statement with respect to the sale of such shares of Common Stock has been
declared effective by the Commission and such shares of Common Stock have been
disposed of pursuant to such effective Registration Statement, (ii) such shares
of Common Stock shall have been or could be sold under circumstances in which
all of the applicable conditions of (x) Rule 144 (k) (or any similar provisions
then in force) under the Securities Act are met, or (y) Rule 144 (or any similar
provisions then in force) under the Securities Act are met; provided that with
respect to

<PAGE>

this clause (y) the number of shares of Registrable Securities at the time in
question is less than the volume limitations imposed by Rule 144 (e), (iii) such
shares of Common Stock have been otherwise transferred and the Company has
delivered a new certificate or other evidence of ownership for such Common Stock
not bearing a restrictive legend and not subject to any stop order and such
Common Stock may be publicly resold by the person receiving such certificate
without complying with the registration requirements of the Securities Act, or
(iv) such shares of Common Stock shall have ceased to be outstanding."

                                   ARTICLE V
                              AFFIRMATIVE COVENANTS
                              ---------------------

   For so long as the Note is outstanding, the Company shall:

         SECTION 5.1 Corporate Existence. The Company will preserve and keep in
full force and effect its corporate existence and the corporate existence of
each its Subsidiaries (unless merged into the Company) and all rights and
franchises of the Company and its Subsidiaries unless, in the good faith
judgment of the Company, the termination of or failure to preserve or keep in
full force and effect such corporate existence, right or franchise could not
reasonably have a Material Adverse Effect.

         SECTION 5.2 Maintenance of Properties. The Company will, and will cause
each of its Subsidiaries to, maintain all of its properties necessary for the
conduct of its business in good condition, repair and working order (normal wear
and tear excepted) and cause to be made all necessary repairs, renewals,
replacements, betterments and improvements thereof, all as in the judgment of
the Company may be necessary so that the business carried on in connection
therewith may be conducted at all times; provided, however, that nothing in this
Section 5.2 shall prevent the Company or any of its Subsidiaries from
discontinuing the operation and maintenance of any of such properties if such
discontinuance is, in the judgment of the Company, desirable in the conduct of
such Person's business and does not cause a Material Adverse Effect.

         SECTION 5.3 Insurance. Each of the Company and its Subsidiaries will
maintain with financially sound and reputable insurance companies, funds or
underwriters, insurance of the kinds, covering the risks and in the relative
proportionate amounts usually carried by reasonable and prudent companies
conducting businesses similar to that of the Company and its Subsidiaries.

         SECTION 5.4 Compliance with Law. The Company will and will cause each
of its Subsidiaries to comply in all material respects with all laws, ordinances
or governmental rules or regulations to which each of them is subject and will
obtain and maintain in effect all licenses, certificates, permits, franchises
and other governmental authorizations necessary to the ownership of their
respective properties or to the conduct of their respective businesses, in each
case to the extent necessary to ensure that non-compliance with such laws,
ordinances or governmental rules or regulations or failures to obtain or
maintain in effect such licenses, certificates, permits, franchises

<PAGE>

and other governmental authorizations could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect.

         SECTION 5.5 Taxes. The Company will and will cause each of its
Subsidiaries to file all tax returns required to be filed in any jurisdiction
and to pay and discharge all Taxes shown to be due and payable on such returns
and all other Taxes, assessments, governmental charges, or levies imposed on
them or any of their properties, assets, income or franchises, to the extent
such Taxes and assessments have become due and payable and before they have
become delinquent and all claims for which sums have become due and payable that
have or might become a Lien on properties or assets of the Company or any such
Subsidiary, provided that neither the Company nor any such Subsidiary need pay
any such Tax or assessment or claims if (i) the amount, applicability or
validity thereof is contested by the Company or such Subsidiary on a timely
basis in good faith and in appropriate proceedings, and the Company or such
Subsidiary has established adequate reserves therefor in accordance with GAAP on
the books of the Company or such Subsidiary or (ii) the nonpayment of all such
Taxes and assessments in the aggregate could not reasonably be expected to have
a Material Adverse Effect.

         SECTION 5.6 Inspection of Properties and Books. Within five (5)
Business Days of receiving notice (describing with reasonable particularity the
books and records to be reviewed), the Company and its Subsidiaries shall permit
Investor and its designated representatives to visit and inspect any of the
properties of the Company and its Subsidiaries, to examine the books of account
of the Company and its Subsidiaries (and to make copies thereof and extracts
therefrom), and to discuss the affairs, finances and accounts of each of the
Company and its Subsidiaries with, and to be advised as to the same by, officers
or partners of such Persons, during normal business hours, in a manner
calculated not to disrupt ongoing business activities and at such intervals as
such Investor may reasonably request.

                                   ARTICLE VI
                                   DEFINITIONS
                                   -----------

         As used herein, in addition to the terms defined elsewhere herein, the
following terms shall have the following meanings.

         "Capital Stock" means, as to any Person that is a corporation, the
authorized shares of such Person's capital stock, including all classes of
common, preferred, voting and nonvoting capital stock, and, as to any Person
that is not a corporation or an individual, the ownership interests in such
Person, including, without limitation, the right to share in profits and losses,
the right to receive distributions of cash and property, and the right to
receive allocations of items of income, gain, loss, deduction and credit and
similar items from such Person, whether or not such interests include voting or
similar rights entitling the holder thereof to exercise control over such
Person.

<PAGE>

         "Charter" means the articles or certificate of incorporation, statute,
constitution, joint venture or partnership agreement or articles or other
organizational document of any Person other than an individual, each as from
time to time amended or modified.

         "Code" means the Internal Revenue Code of 1986, as amended.

         "Common Stock" means the shares of common stock, $0.001 par value per
share, of the Company.

         "Exchange Act" means the Securities Exchange Act of 1934, as amended,
or any successor federal statute, and the rules and regulations of the
Securities and Exchange Commission thereunder, all as the same shall be in
effect at the time.

         "Generally accepted accounting principles" or "GAAP" means accounting
principles which are (a) consistent with the principles promulgated or adopted
by the Financial Accounting Standards Board and its predecessors and other
recognized principle setting bodies, in effect from time to time, (b) applied on
a basis consistent with prior periods, and (c) such that a certified public
accountant would, insofar as the use of accounting principles is pertinent, be
in a position to base an opinion as to financial statements in which such
principles have been properly applied.

         "Person" means an individual, partnership, corporation, association,
trust, joint venture, unincorporated organization, and any government,
governmental department or agency or political subdivision thereof.

         "Preferred Stock" means the shares of preferred stock, $0.001 par value
per share, of the Company.

         "Qualified Shares" means the shares of Preferred Stock (other than the
shares of Series H Stock) issuable upon conversion of the Note.

         "Registration Rights Agreement" means that certain Registration Rights
Agreement, dated May 15, 2002, by and between the Company and the Investor.

         "Securities Act" means the Securities Act of 1933, as amended, or any
successor federal statute, and the rules and regulations of the Securities and
Exchange Commission thereunder, all as the same shall be in effect at the time.

         "Series H Stock" means the Series H Cumulative Accelerating Redeemable
Preferred Stock, $0.001 par value per share, of the Company.

         "Subsidiary" means any Person which the Company now or hereafter shall
at the time own, directly or indirectly through a subsidiary, at least a
majority of the outstanding Capital Stock (or other beneficial interest)
entitled to vote generally; and the term "Subsidiaries" means all of such
Persons collectively.

         "Taxes" means (A) all net income, gross income, gross receipts, sales,
use, ad valorem, transfer, franchise, profits, license, withholding, payroll,
employment, excise, severance, stamp, occupation, premium, property or windfall
profits taxes, or other taxes of any kind whatsoever,

<PAGE>

together with any interest and any penalties, additions to tax or additional
amounts imposed by any taxing authority (domestic or foreign) upon the Company
with respect to all periods or portions thereof ending on or before the date
hereof and/or (B) any liability of the Company for the payment of any amounts of
the type described in the immediately preceding clause (A) as a result of being
a member of an affiliated or combined group.

         "Transaction Costs" means any and all costs, fees and expenses of any
broker, finder or placement agent incurred by the Company in connection with the
transactions contemplated by this Agreement or any Related Agreement.

         "Underlying Shares" means, as applicable, the shares of Series H Stock
or the Qualified Shares issuable upon conversion of the Note.

                                   ARTICLE VII
                                  MISCELLANEOUS
                                  -------------

         SECTION 7.1 Fees and Expenses. The Company will bear all of its own
expenses in connection with the preparation, negotiation and execution of this
Agreement, and will also reimburse the Investor for, or pay, any reasonable,
documented expenses it incurs, upon submission of supporting documentation
thereof and subject to Section 1.2(b)(ii) hereof, in connection with the
preparation, execution and negotiation of this Agreement.

         SECTION 7.2 Survival. The representations, warranties, covenants and
agreements of the Company under or pursuant to this Agreement shall survive for
a period of 36 months following the execution and delivery of this Agreement.

         SECTION 7.3 Entire Agreement. This Agreement and any other agreement or
instrument to be delivered expressly pursuant to the terms hereof constitute the
entire agreement between the parties hereto with respect to the subject matter
hereof and supersede all previous negotiations, commitments and writings with
respect to such subject matter.

         SECTION 7.4 Assignments; Parties in Interest. Neither this Agreement
nor any of the rights, interests or obligations hereunder may be assigned by any
of the parties hereto (whether by operation of law or otherwise) without the
prior written consent of the other parties. This Agreement shall be binding upon
and inure solely to the benefit of each party hereto, and nothing herein,
express or implied, is intended to or shall confer upon any Person not a party
hereto any right, benefit or remedy of any nature whatsoever under or by reason
hereof, except as otherwise provided herein.

         SECTION 7.5 Amendments.

            (a) No failure or delay on the part of any of the parties hereto in
exercising any right, power or remedy hereunder shall operate as a waiver
thereof, nor shall any single or partial

<PAGE>

exercise of any such right, power or remedy preclude any other or further
exercise thereof or the exercise of any other right, power or remedy. The
remedies provided for in this Agreement are cumulative and are not exclusive of
any remedies that may be available to the parties hereto at law, in equity or
otherwise.

            (b) Any amendment, supplement or modification of or to any provision
of this Agreement or the Note, any waiver of any provision of this Agreement or
the Note and any consent to any departure by any party from the terms of any
provision of this Agreement or the Note shall be effective only if it is made or
given in writing and signed by the Company and the Required Holders (as defined
below); provided, however, that no such amendment, supplement, modification or
waiver may, without the written consent of the Holder of each Note at the time
outstanding affected thereby (A) change the amount or time of any payment or
prepayment of principal of, or reduce the rate or change the time of payment or
method of computation of interest on, the Notes, (B) change the percentage of
the principal amount of the Notes the Holders of which are required to consent
to any such amendment, supplement, modification. Required Holders shall mean
with respect to this Agreement or the Notes, at any time, the holders of
outstanding Notes representing at least a majority of the aggregate principal
amount of the Notes then outstanding.

            (c) Any amendment or waiver consented to as provided in this Section
6.5 is binding upon each future holder of any Note (as applicable) and upon the
Company without regard to whether such Note has been marked to indicate such
amendment or waiver. No course of dealing between the Company and any holder of
a Note nor any delay in exercising any rights hereunder or under the Note shall
operate as a waiver of any rights of any holder of such securities.

         SECTION 7.6 Descriptive Headings. The descriptive headings of this
Agreement are inserted for convenience of reference only and do not constitute a
part of and shall not be utilized in interpreting this Agreement.

         SECTION 7.7 Notices and Addresses. Any notice, demand, request, waiver,
or other communication under this Agreement shall be in writing and shall be
deemed to have been duly given on the date of service, if personally served or
sent by facsimile; on the business day after notice is delivered to a courier or
mailed by express mail, if sent by courier delivery service or express mail for
next day delivery; and on the third day after mailing, if mailed to the party to
whom notice is to be given, by first class mail, registered, return receipt
requested, postage prepaid and addressed as follows:

To Company:                OnCure Technologies Corp.
                           610 Newport Center Drive, Suite 350
                           Newport Beach, CA 92660
                           Attn: Jeffrey A. Goffman
                           Fax:  (949) 721-6540

<PAGE>

                           With a copy to:

                           Scott M. Zimmerman, Esq.
                           Swidler Berlin Shereff Friedman, LLP
                           The Chrysler Building
                           405 Lexington Avenue
                           New York, NY  10174
                           Fax:  (212) 891-9598

To Holder:                 Alpine Venture Capital Partners LP
                           One North Clematis Street, Suite 510
                           West Palm Beach, FL 33401
                           Attn: Stephen J. Warner
                           Fax:  (561) 838-4105

                           With a copy to:

                           Peter J. Sheptak, Esq.
                           Edwards & Angell, LLP
                           One North Clematis Street, Suite 400
                           West Palm Beach, FL 33401
                           Fax:  (561) 655-8719

         SECTION 7.8 Severability. In the event that any provision of this
Agreement becomes or is declared by a court of competent jurisdiction to be
illegal, void or unenforceable, the remainder of this Agreement will continue in
full force and effect and the application of such provision to other Persons or
circumstances will be interpreted so as reasonably to effect the intent of the
parties hereto. The parties further agree to replace such void or unenforceable
provision of this Agreement with a valid and enforceable provision that will
achieve, to the extent possible, the economic, business and other purposes of
such void or unenforceable provision.

         SECTION 7.9 Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of Florida, regardless of the
laws that might otherwise govern under applicable principles of conflicts of
laws thereof. EACH PARTY HEREBY IRREVOCABLY CONSENTS TO THE JURISDICTION OF ANY
STATE OR FEDERAL COURT SITTING IN PALM BEACH COUNTY, FLORIDA IN ANY ACTION OR
PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE NOTE, THE MAY NOTE,
THE PRIOR AGREEMENT (AND ALL RELATED AGREEMENTS (AS DEFINED IN THE PRIOR
AGREEMENT)), AS WELL AS TO THE JURISDICTION OF ALL COURTS TO WHICH AN APPEAL MAY
BE TAKEN FROM SUCH COURTS.

<PAGE>

         SECTION 7.10 Counterparts; Facsimile Signatures. This Agreement may be
executed in one or more counterparts, all of which shall be considered one and
the same agreement and shall become effective when one or more counterparts have
been signed by each of the parties and delivered to the other party, it being
understood that all parties need not sign the same counterpart. This Agreement
may be executed by facsimile, and a facsimile signature shall have the same
force and affect as an original signature on this Agreement.

                                   (SIGNATURE PAGE FOLLOWS)

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first above written.

                                   ONCURE TECHNOLOGIES CORP.

                                   By:  /s/ Jeffrey A. Goffman
                                        ----------------------------
                                        Name:  Jeffrey A. Goffman
                                        Title: President and Chief Executive
                                               Officer

                                   ALPINE VENTURE CAPITAL PARTNERS LP
                                   By: Alpine Venture Capital Corp., its general
                                         partner

                                   By:  /s/ Steven J. Warner
                                        ----------------------------
                                        Name:  Steven J. Warner
                                        Title: Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00050-of-00352.parquet"}]]